1832 Asset Management
TXG icon

1832 Asset Management’s 10x Genomics TXG Stock Holding History

1832 Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-269,000
Closed -$53M – 888
2021
Q2 		$53M Buy
+269,000
New +$48.7M 0.1% 164

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1832 Asset Management's TXG Position: Q3 2021 in Review

1832 Asset Management sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 269,000 shares — an estimated $53M sold.

1832 Asset Management first reported a position in TXG in Q2 2021 and held it in 1 quarter. The position peaked at $53M in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

  • 1832 Asset Management reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
  • 1832 Asset Management sold 269,000 10x Genomics shares in Q3 2021, an estimated $53M.
  • 1832 Asset Management first reported a position in 10x Genomics in Q2 2021 and held it in 1 quarter.
  • 1832 Asset Management's 10x Genomics position peaked at $53M in Q2 2021.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on 1832 Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.